<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99141">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01907958</url>
  </required_header>
  <id_info>
    <org_study_id>CLINPRADIA</org_study_id>
    <nct_id>NCT01907958</nct_id>
  </id_info>
  <brief_title>Management of Albuminuria in Hypertensive Diabetics</brief_title>
  <acronym>CLINPRADIA</acronym>
  <official_title>A Multicentre Study to Evaluate the Management of Microalbuminuria in Hypertensive Patients With Type 2 Diabetes: Improving Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medpharmgene, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medpharmgene, Inc.</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter stepped wedge cluster randomized trial of family practice clinics in Quebec and
      Ontario comparing the effect of introducing a Point of Care testing (POCT) for urine albumin
      to usual practice on quality of care in hypertensive patients with Type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Stabilisation or improvement of urine albumin excretion status by at least one stage</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microalbuminuria (or further stages of CKD) after 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Demographics, medical history and medication Diabetes and hypertension status Blood pressure measurements</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Microalbuminuria</condition>
  <condition>Hypertension</condition>
  <condition>Type 2 Diabetes</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        18 years and older Uncontrolled blood pressure Type 2 diabetes
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 years and older and able to visit the study sites every 3 months

          -  T2D patients with ongoing anti-diabetic therapy for at least 5 years

          -  Uncontrolled hypertension according to 2012 CHEP recommendations for management of
             hypertension in diabetic patients ( i.e. BP&gt; 130/80 mmHg)

          -  Able and agreeing to provide informed consent.

        Exclusion Criteria:

          -  Type 1 diabetes patients

          -  Ongoing therapy with perindopril,

          -  Known hypersensitivity or allergies to ACEI or  sulfonamide derivatives,

          -  A history of angioedema related or not to previous treatment with ACEI,

          -  Impaired renal function defined as serum creatinine levels &gt; 177 µmol/L, eGFR  &lt;30
             mL/min,

          -  Hyperkalemia or hypokalemia,

          -  Severe hepatic impairment,

          -  Use of non-antiarrhythmic agents causing torsade de pointes,

          -  Pregnant or lactating women, or who are planning to become pregnant,

          -  Any conditions which may impact on participation according to treating physician.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie-Renée GUERTIN, project manager</last_name>
    <phone>514 249 4209</phone>
    <phone_ext>222</phone_ext>
    <email>m-r.guertin@medpharmgene.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medpharmgene</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1Y 3L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Renée Guertin, Project manager</last_name>
      <phone>514 249 4209</phone>
      <phone_ext>222</phone_ext>
      <email>m-r.guertin@medpharmgene.ca</email>
    </contact>
    <investigator>
      <last_name>Pavel Hamet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 24, 2013</lastchanged_date>
  <firstreceived_date>July 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microalbuminuria</keyword>
  <keyword>Hypertensive</keyword>
  <keyword>Diabetics</keyword>
  <keyword>urine albumin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
